FREMONT, CA, Alamar Biosciences, a precision proteomics company, has closed its $80 million Series B financing round led by Sherpa Healthcare Partners.
Alamar Biosciences, a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, has closed its $80 million Series B financing round, bringing its total funding to $110 million.
The Series B financing round was led by Sherpa Healthcare Partners and included Morningside Ventures, Samsara Biocapital, and existing investors Qiming Venture Partners and Illumina Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
